```html

Vaccine‑Derived Poliovirus Infection

Overview

Vaccine‑derived poliovirus (VDPV) infection is a rare but serious condition that occurs when the weakened polio virus used in the oral polio vaccine (OPV) mutates and regains the ability to cause disease. While the majority of the world now uses an inactivated polio vaccine (IPV), OPV is still administered in some low‑resource settings because it is cheap, easy to give, and provides strong intestinal immunity. When OPV‑derived viruses circulate in under‑immunized communities they can evolve into circulating VDPV (cVDPV) or cause isolated cases known as immunodeficiency‑associated VDPV (iVDPV).

• Who it affects: Primarily children under 5 years old in areas with low vaccination coverage, and individuals with primary immunodeficiencies who cannot clear the vaccine virus.
• Global prevalence: As of 2023, the WHO reported 1,658 cases of cVDPV (mainly type 2) across 30 countries, representing <1 % of all poliovirus infections worldwide. iVDPV cases are even rarer—fewer than 30 documented cases since 1961.

Because VDPV behaves like wild‑type poliovirus, it can lead to paralytic poliomyelitis, muscle weakness, and in severe cases, death. Early recognition and prompt public‑health response are essential to stop outbreaks.

Symptoms

Symptoms of VDPV infection mirror those of classic poliomyelitis and generally follow a three‑phase pattern: non‑specific prodrome, aseptic meningitis (rare), and paralytic disease.

1. Prodromal (flu‑like) phase – 1–7 days

• Fever: Low‑grade to high, often 38‑40 °C (100.4‑104 °F).
• Sore throat and difficulty swallowing.
• Headache.
• Gastrointestinal upset: Nausea, vomiting, abdominal pain, or diarrhea.
• General malaise.

2. Aseptic meningitis (≈5 % of cases)

• Stiff neck, photophobia, and severe headache.
• Vomiting without a clear gastrointestinal cause.
• Altered mental status (confusion or lethargy) in rare severe forms.

3. Paralytic (most serious) phase – 1–3 weeks after onset

• Asymmetric muscle weakness: Usually starts in the legs and can progress upward.
• Loss of reflexes (areflexia).
• Facial muscle weakness or drooping.
• Difficulty breathing: Involvement of the diaphragm (ventilatory failure) may require mechanical ventilation.
• Painful muscle cramps.
• Post‑polio syndrome (years later): New‑onset fatigue, pain, and muscle weakness in previously affected individuals.

Not all infected individuals develop paralysis; up to 90 % experience only the mild, flu‑like illness.

Causes and Risk Factors

How VDPV develops

1. Oral Polio Vaccine (OPV) administration: OPV contains live, attenuated (weakened) poliovirus of one or more serotypes (type 1, 2, or 3).
2. Replication in the gut: The vaccine virus replicates in the intestinal tract, inducing immunity.
3. Genetic drift: In a poorly immunized population, the attenuated virus can circulate for months, accumulating mutations. When the virus regains neurovirulence, it becomes VDPV.
4. Transmission: VDPV spreads fecal‑orally, especially in areas with inadequate sanitation.

Key risk factors

• Low OPV coverage (<80 %): Allows the virus to circulate unchecked.
• Poor sanitation and overcrowding: Facilitates fecal‑oral spread.
• Primary immunodeficiency disorders (e.g., agammaglobulinemia, common variable immunodeficiency): These individuals cannot clear the vaccine virus, leading to prolonged excretion and iVDPV.
• Travel to or residence in regions with ongoing cVDPV outbreaks.
• Use of monovalent or bivalent OPV without adequate type‑2 immunity: Type‑2 VDPV accounts for >90 % of cVDPV cases.

Diagnosis

Prompt laboratory confirmation is essential both for patient management and for public‑health containment.

Clinical suspicion

• Acute flaccid paralysis (AFP) in a child <5 years old, especially with recent OPV exposure.
• History of immunodeficiency with prolonged poliovirus shedding.

Laboratory tests

1. Stool specimen: The gold standard. Two samples collected 24–48 hours apart are cultured for poliovirus.
2. Throat swab or cerebrospinal fluid (CSF): Used when stool is unavailable or to assess CNS involvement.
3. Real‑time PCR: Detects poliovirus RNA quickly; sequencing determines if it is vaccine‑derived and its degree of mutation.
4. Serology: Neutralizing antibody titers can show immunity status but are not diagnostic.
5. Genetic sequencing: Differentiates VDPV from wild‑type poliovirus and identifies serotype.

Imaging

• MRI of the spine or brain may reveal inflammation of the anterior horn cells, supporting a diagnosis of paralytic poliomyelitis.

Treatment Options

There is no specific antiviral therapy that eradicates poliovirus, so treatment focuses on supportive care, prevention of complications, and, in selected cases, immunologic interventions.

Acute management

• Hospitalization: Recommended for any paralytic case or severe meningitis.
• Respiratory support: Mechanical ventilation for diaphragmatic involvement.
• Physical therapy: Early, gentle mobilization to preserve muscle tone and prevent contractures.
• Analgesics: Acetaminophen or ibuprofen for pain and fever.

Immunologic approaches (iVDPV)

• Intravenous immunoglobulin (IVIG): May reduce viral shedding in immunodeficient patients.
• Monoclonal antibodies (experimental): Ongoing trials investigate anti‑poliovirus antibodies.

Antiviral research

Compounds such as pocapavir and favipiravir have shown in‑vitro activity against poliovirus, but data are limited, and they are not yet approved for routine use.

Long‑term care

• Orthopedic interventions for joint deformities.
• Assistive devices (braces, wheelchairs).
• Psychosocial support for patients and families.

Living with Vaccine‑Derived Poliovirus Infection

Managing the aftermath of VDPV infection requires a multidisciplinary approach.

Daily management tips

• Physical therapy schedule: Attend PT sessions 2–3 times per week; perform home exercises daily.
• Respiratory hygiene: Use incentive spirometry, monitor breathing patterns, and seek help if you notice shortness of breath.
• Skin care: Prevent pressure sores by repositioning every 2 hours if wheelchair‑bound.
• Nutrition: High‑protein diet supports muscle repair; consider a dietitian if swallowing is impaired.
• Vaccination status: Ensure all routine vaccines (including IPV) are up‑to‑date to avoid co‑infection.
• Regular follow‑up: Neurologist, pulmonologist, and immunologist visits at least every 6 months.
• Psychological wellbeing: Join support groups; counseling can help cope with disability.

Monitoring for recurrence

People with iVDPV should provide stool samples every 3 months until two consecutive negatives are documented, as recommended by the WHO Global Polio Eradication Initiative.

Prevention

Because VDPV arises from the vaccine virus itself, prevention strategies focus on maintaining high immunity while minimizing OPV use where safe.

• Maintain > 95 % immunization coverage: Ensures herd immunity that halts virus circulation.
• Switch to Inactivated Polio Vaccine (IPV): IPV does not contain live virus; many high‑income countries have fully transitioned.
• Targeted OPV campaigns: Limited, high‑quality campaigns in outbreak zones, followed by IPV booster doses.
• Improve sanitation: Access to clean water, proper sewage disposal, and hand‑washing reduce fecal‑oral spread.
• Screening of immunodeficient patients: Before OPV administration, evaluate for primary immunodeficiencies and consider IPV instead.
• Surveillance: Acute flaccid paralysis reporting and environmental stool sampling help detect VDPV early.

Complications

If VDPV infection is not promptly treated or if paralysis occurs, several complications can develop:

• Permanent motor weakness: May be asymmetric and involve the respiratory muscles.
• Post‑polio syndrome (PPS): Occurs 15–40 years after the initial infection; patients experience new fatigue, muscle pain, and progressive weakness.
• Orthopedic problems: Joint contractures, scoliosis, and limb deformities.
• Respiratory failure: Chronic ventilator dependence in severe cases.
• Urinary tract infections: Result from bladder dysfunction due to neurogenic abnormalities.
• Psychosocial impact: Depression, anxiety, and reduced quality of life.

When to Seek Emergency Care

Call emergency services (911/112) or go to the nearest emergency department if you notice any of the following:

• Sudden onset of weakness or paralysis in the arms or legs, especially if it progresses rapidly.
• Difficulty breathing, shortness of breath, or a feeling of “choking.”
• Severe, persistent fever (> 39 °C / 102 °F) that does not improve with fever‑reducing medication.
• Loss of consciousness, severe headache with neck stiffness, or confusion.
• Sudden inability to swallow or speak.

Prompt medical attention can be life‑saving and helps prevent spread to others.

References

• Mayo Clinic. “Poliomyelitis.” Updated 2023. https://www.mayoclinic.org
• World Health Organization. “Vaccine‑derived polioviruses (VDPVs).” 2024. https://www.who.int
• Centers for Disease Control and Prevention. “Polio – Overview.” 2024. https://www.cdc.gov
• National Institutes of Health. “Primary Immunodeficiency and Vaccine‑Derived Poliovirus.” 2022. https://www.ncbi.nlm.nih.gov
• Cleveland Clinic. “Paralytic Polio: Symptoms, Causes, and Treatment.” 2023. https://my.clevelandclinic.org
• J. R. Kew et al., “Outbreak of circulating vaccine‑derived poliovirus—type 2, Manikhali, Bangladesh, 2022,” *Emerging Infectious Diseases*, 2023.

```